Plain-English translation of NCT07629583 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Lupus Erythematosus, Systemic research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new experimental medication called for people with systemic lupus erythematosus (lupus)—an autoimmune disease where the body attacks its own tissues—especially in those whose kidneys are also affected. Researchers want to understand how safe this medication is, how well your body tolerates it, and how it works in your system. This is an early-stage study (Phase 1b), which means the medication has shown promise in labs but is now being tested in real patients for the first time.
Many people with lupus don't respond well enough to current treatments or can't tolerate them. This medication works differently than existing options, targeting a specific part of the immune system involved in lupus, so researchers believe it could help patients who have exhausted other treatment choices.
You likely qualify if…
You likely don't qualify if…
You will receive the medication in a carefully planned dosing schedule that starts low and gradually increases to a target dose. The study has two stages: first, researchers will test increasing doses in a smaller group to ensure safety, then expand to more participants. You will likely visit the clinic multiple times for blood tests, kidney function checks, and monitoring of your lupus symptoms to see how the medication affects your disease and your body's response to it.
AI-generated summary from trial data · Aug 9, 2026 · Not medical advice
Spain